Text Size

Choline Quantification in Breast Cancer by MRS

This study has been completed.
Sponsor:
Collaborator:
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00201487
First received: September 16, 2005
Last updated: August 25, 2011
Last verified: August 2011
History of Changes
  Purpose

Choline has been found in increased concentration in breast cancer patients. Hypothesis: The choline signal as observed by MRS is sensitive to treatment, and a positive response to treatment will give a reduction in choline concentration.

The purpose of this study is to establish methods for quantification of choline in breast cancer by MRS


Condition
Breast Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Choline Quantification in Breast Cancer by MRS

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Norwegian University of Science and Technology:

Enrollment: 10
Study Start Date: November 2007
Study Completion Date: June 2009
Detailed Description:
  1. Establishment of new MRS sequence for choline quantification of choline. This sequence is choline-selective, and signals from water and lipids are suppressed simultaneously.
  2. Compare to different methods for choline quantification. The first method is quantification through an external phantom standard, containing a known concentration of choline. The other method is based on the utilisation of internal water signal as a reference.

Both calculations can be performed from the same MR exam. Ten patients will be included in the study.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

breast cancer

Criteria

Inclusion Criteria:

  • breast cancer

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00201487

Sponsors and Collaborators
Norwegian University of Science and Technology
The Norwegian Women´s Public Health Association
Investigators
Principal Investigator: Tone Bathen, PhD NTNU, Faculty of medicine,
  More Information

No publications provided

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00201487     History of Changes
Other Study ID Numbers: 11870
Study First Received: September 16, 2005
Last Updated: August 25, 2011
Health Authority: Norway: Norwegian Social Science Data Services

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Choline
Lipotropic Agents
Hypolipidemic Agents
 Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Lipid Regulating Agents
Nootropic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on June 18, 2013